Raj Reddy
Raj is the founder and CEO of Canary Cure, leading the team responsible for the groundbreaking discovery and development of a first-in-class RNA gene-silencing therapeutic approach to treating metabolic disease. This innovative approach targets both the CB1 receptor and key thermogenic genes, offering a potential paradigm shift in the fight against obesity and its associated complications.
With over 20 patents filed in genetics and RNA therapy, Raj’s background in pharmacology and medicinal chemistry and a deep understanding of the endocannabinoid system and its implications for metabolic health positions Canary to develop a pipeline of novel therapeutics. Recognizing the promise of the company’s approach, Canary’s scientific advisory board has attracted some of the industry’s best scientists and key opinion leaders in gene and RNA therapy, all committed to advancing this exciting field.
In addition to his experience in pharmacology, Raj also has extensive experience in global strategic management, specialty biologicals, and market access, having overseen a portfolio exceeding $500 million. Notably, he led the risk management therapeutics team that launched multiple myeloma products for Celgene, and his clinical team's innovative work was recognized with the Cancer Care Ontario award.
A seasoned biotech executive, Raj is passionate about forging strategic partnerships to accelerate the development and commercialization of transformative therapies. He has successfully established collaborations with leading institutions from large hospital systems to leading research universities focused on gene therapy development and novel med-tech advancements.
Abstracts this author is presenting: